A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2016
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Apr 2015 New trial record